Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs LCL 161 (Primary) ; Cyclophosphamide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2018 Status changed from recruiting to completed.
- 21 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.